Related Experiment Videos
Emerging oral drugs for erectile dysfunction.
Alberto Briganti1, Andrea Salonia, Andrea Gallina
1Cattedra di Urologia, University Vita e Salute-San Raffaele, Milan, Italy.
Expert Opinion on Emerging Drugs
|May 25, 2004
Summary
Erectile dysfunction (ED) treatments, including PDE5 inhibitors like sildenafil, tadalafil, and vardenafil, offer effective oral options. Sublingual apomorphine is an alternative, though less commonly used due to side effects.
Area of Science:
- Urology
- Pharmacology
- Andrology
Background:
- Erectile dysfunction (ED) significantly impacts men's sexual health globally.
- Oral pharmacotherapy is the primary treatment approach for most ED patients.
- Phosphodiesterase type 5 (PDE5) inhibitors are widely used and effective ED medications.
Purpose of the Study:
- To review recent advancements in oral therapies for erectile dysfunction.
- To analyze the clinical and pharmacological profiles of PDE5 inhibitors and sublingual apomorphine.
- To provide an overview of current ED treatment options.
Main Methods:
- Literature review focusing on clinical and pharmacological data.
- Analysis of efficacy and safety profiles of oral ED medications.
- Comparison of PDE5 inhibitors (sildenafil, tadalafil, vardenafil) and sublingual apomorphine.
Main Results:
- Sildenafil, tadalafil, and vardenafil are effective PDE5 inhibitors with favorable safety profiles.
- Sublingual apomorphine shows efficacy in mild-to-moderate ED but has limited use due to side effects like nausea.
- Patients unresponsive to oral therapy may consider intracavernosal or intraurethral treatments.
Conclusions:
- Oral PDE5 inhibitors represent a highly effective first-line treatment for erectile dysfunction.
- Sublingual apomorphine offers an alternative but is limited by its side effect profile.
- Further research and development in oral ED therapies continue to improve patient outcomes.